Observational study / 2011
Higher serum enterolactone levels were linked to significantly reduced risk of death in postmenopausal breast cancer patients.
Researchers assessed the prognosis of 1,140 postmenopausal breast cancer patients followed for a median of 6.1 years. Median enterolactone levels were 17.0 nmol/L in deceased patients and 21.4 nmol/L in living patients, with 162 total deaths confirmed. Higher serum enterolactone was associated with significantly reduced risk of death (HR per 10 nmol/L increment, 0.94; P = .04; HR for the highest quartile, 0.58; 95% CI, 0.34 to 0.99). For distant disease, the HR was 0.94 per 10 nmol/L (P = .08) and 0.62 (95% CI, 0.35 to 1.09) in the highest quartile. The highest quartile was associated with significantly reduced death risk only in estrogen receptor-negative tumors (HR, 0.27; 95% CI, 0.08 to 0.87), not in estrogen receptor-positive tumors (HR, 0.91; 95% CI, 0.45 to 1.84).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 1,140 postmenopausal breast cancer patients aged 50-74 years diagnosed 2002-2005
- What was measured
- Overall survival and distant disease-free survival
THE PAPER
Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J. J Clin Oncol, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.